Brean Murray initiates coverage on ImmunoGen, Inc. (Nasdaq: IMGN) with a Buy rating and $14 Target Price

Brean analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE